Clinical Trial Update: Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma [Phase 3]

View source ↗

Summary

Phase 3 study evaluating chemotherapy with or without bevacizumab for recurrent or metastatic head and neck squamous cell carcinoma; results were posted in 2019…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Hypopharyngeal Squamous Cell Carcinoma
• Laryngeal Squamous Cell Carcinoma
• Oral Cavity Squamous Cell Carcinoma
• Oropharyngeal Squamous Cell Carcinoma
• Salivary Gland Squamous Cell Carcinoma
• Sinonasal Squamous Cell Carcinoma
• Tongue Squamous Cell Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Neck Squamous Cell Carcinoma of Unknown Primary, Recurrent Hypopharyngeal Squamous Cell Carcinoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2019-11-15